CSI Market
Sign In | Register

Beone Medicines Ltd (ONC) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access ONC quarterly Cash Flow →
Cash flow patterns shown here provide context for understanding Beone Medicines Ltd's ability to sustain operations and capital deployment.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income286.93
Depreciation & amortization141.69
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-93.17
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation510.86
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Gains Losses From Decrease Increase In Fair Value Of Financial Instruments-
Available For Sale Securities Gross Realized Gain Loss Net-
Interest Expense Operating Activities-
Acquired In Process Research And Development0.69
Marketable Securities Realized Gain Loss-
Increase Decrease In Contract With Customer Asset-
Increase Decrease In Operating Lease Right of Use Asset-
Amortization Of Research And Development Financing Liability-101.10
Increase Decrease In Contract With Customer Liability1.29
Gain Loss Related To Litigation Settlement-
Increase Decrease In Noncash Interest Expense14.87
Income taxes9.47
Gain (Loss) on Investments-0.60
Accounts Receivable146.81
Increase (Decrease) in Accounts Payable79.83
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital56.13
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities73.87
Discontinued operations0.00
Net Cash flow from Operating Activities1,127.58
Investing Activities
Capital Expenditures-205.84
Sale of Capital Items0.00
Proceeds from Sale of Available-for-sale Securities, Debt3.45
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payment Of Auction Deposit To Acquire Land-
Payments To L and Use Rights-
Cash Acquired From Acquisition Net Of Cash Paid-
Payments To Acquire Other Investments Time Deposits-
Payments To Purchase In Process Research And Development-60.69
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Long-term Investments-11.83
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities-1.24
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-276.16
Financing Activities
Short-term debt Net-811.11
Other borrowing transactions-23.39
Long-term debt - borrowings1,761.59
Long-term debt - repayments-35.68
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock196.28
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-2,708.27
Payments Of Temporary Equity Issuance Costs-
Proceeds From Long Term Bank Loan-
Proceeds From Issuance Public Offering-
Proceeds From Warrant Exercises And Stock Options Exercised-
Proceeds From Issuance Of Common Stock Net Of Stock Issuance Costs-
Proceeds From Issuance Of Common Stock Net Of Underwriter Discount-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents2,638.75
Restricted Cash And Cash Equivalents At Carrying Value41.28
Proceeds from Common Stock Issuance and Initial Public Offering-
Payments of Initial Public Offering Cost and Stock Issuance Cost-
Proceeds From Common Stock Issuance And Initial Public Offering-
Payments Of Initial Public Offering Cost And Stock Issuance Cost-
Proceeds From Research And Development Financing Liability-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities1,059.45
Effect of exchange rate on cash flow60.02
Discontinued operations0.00
Free Cash Flow921.74
Total Cash Flow1,970.90
4 historic quarters locked

Sign in to unlock the full Beone Medicines Ltd cash flow history.

Sign In Create Free Account

About Beone Medicines Ltd Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 26, 2026
  • Source: bgne-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-26-011946

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License